MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Transgene Logo
Developing viral immunotherapies like vaccines and oncolytic viruses to treat solid tumors.
France
TNG
TRANS GENIC GROUP INC. Logo
Offers drug discovery CRO services (gene editing, trials) and business investment/consulting.
Japan
2342
TriSalus Life Sciences, Inc. Logo
Oncology tech firm enhancing drug delivery and immunotherapy for solid liver & pancreas tumors.
United States of America
TLSI
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
Tsubota Laboratory Incorporated Logo
Developing pharmaceuticals and medical devices for ophthalmic and brain diseases.
Japan
4890
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America
TYRA
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France
ALUCR
Ulisse Biomed Logo
Provides a portable platform for rapid point-of-need genetic analysis and diagnostics.
Italy
UBM
UNIVERSAL DISPLAY CORP \PA\ Logo
Develops and licenses OLED technologies and materials for the display and lighting industries.
United States of America
OLED

Talk to a Data Expert

Have a question? We'll get back to you promptly.